ライフサイエンスコーパス: ubiquitin-proteasome pathway

1 he KLF5 protein degrades rapidly through the ubiquitin proteasome pathway.

2 G6PD protein expression was mediated by the ubiquitin proteasome pathway.

3 ly unappreciated sites of recognition by the ubiquitin proteasome pathway.

4 crophages by NIK-mediated suppression of the ubiquitin proteasome pathway.

5 age responses are partially regulated by the ubiquitin proteasome pathway.

6 nd could not be stabilized by inhibiting the ubiquitin proteasome pathway.

7 ted by Wee1 tyrosine kinase, a target of the ubiquitin proteasome pathway.

8 ion through recruitment of components of the ubiquitin proteasome pathway.

9 ant group of enzymes that act within the 26S ubiquitin proteasome pathway.

10 suggesting that degradation occurred via the ubiquitin proteasome pathway.

11 ubiquitination and degradation of WRN in the ubiquitin-proteasome pathway.

12 that, upon activation, are degraded via the ubiquitin-proteasome pathway.

13 olyglutamine protein (polyQ) via the nuclear ubiquitin-proteasome pathway.

14 al role in IP(3) receptor processing via the ubiquitin-proteasome pathway.

15 ins and preventing their degradation via the ubiquitin-proteasome pathway.

16 s, which are master growth repressors, via a ubiquitin-proteasome pathway.

17 e that results from enhanced activity of the ubiquitin-proteasome pathway.

18 tubule dynamics, Golgi organization, and the ubiquitin-proteasome pathway.

19 hose degradation is highly regulated via the ubiquitin-proteasome pathway.

20 roteasome system analogous to the eukaryotic ubiquitin-proteasome pathway.

21 s, and that this decrease is mediated by the ubiquitin-proteasome pathway.

22 ption factor 6alpha (ATF6alpha), through the ubiquitin-proteasome pathway.

23 sis protein 1 (COP1) for degradation via the ubiquitin-proteasome pathway.

24 ed in this increasingly important arm of the ubiquitin-proteasome pathway.

25 in and stimulate its degradation through the ubiquitin-proteasome pathway.

26 vents ubiquitination and degradation via the ubiquitin-proteasome pathway.

27 ratin IF network via phosphorylation and the ubiquitin-proteasome pathway.

28 nation, and promotes its degradation via the ubiquitin-proteasome pathway.

29 nhibitor protected synapses, implicating the ubiquitin-proteasome pathway.

30 tein level during the cell cycle through the ubiquitin-proteasome pathway.

31 This occurs via the ubiquitin-proteasome pathway.

32 causing DELLA repressor degradation via the ubiquitin-proteasome pathway.

33 n the degradation of client proteins via the ubiquitin-proteasome pathway.

34 CL12-induced FAK phosphorylation through the ubiquitin-proteasome pathway.

35 bsence of HSP90 activity is dependent on the ubiquitin-proteasome pathway.

36 N is tightly regulated by the Sel10-mediated ubiquitin-proteasome pathway.

37 ases that mediate protein degradation by the ubiquitin-proteasome pathway.

38 al of proteins and organelles depends on the ubiquitin-proteasome pathway.

39 the rapid destruction of Las1 depends on the ubiquitin-proteasome pathway.

40 targeting them for rapid degradation via the ubiquitin-proteasome pathway.

41 that mediates the turnover of HIF-1 via the ubiquitin-proteasome pathway.

42 n by preventing the degradation of Bcl-2 via ubiquitin-proteasome pathway.

43 part of the proteolysis was mediated by the ubiquitin-proteasome pathway.

44 e phosphorylated TFEB for degradation by the ubiquitin-proteasome pathway.

45 to the efficacy of CF drugs that target the ubiquitin-proteasome pathway.

46 teins more susceptible to degradation by the ubiquitin-proteasome pathway.

47 mplex, leading to HIF-1alpha degradation via ubiquitin-proteasome pathway.

48 ease in FMRP that is rapidly degraded by the ubiquitin-proteasome pathway.

49 trix accompanied by rapid degradation by the ubiquitin-proteasome pathway.

50 s, alpha2 is rapidly degraded in vivo by the ubiquitin-proteasome pathway.

51 phy occurs through increased activity of the ubiquitin-proteasome pathway.

52 ausing degradation of DELLA proteins via the ubiquitin-proteasome pathway.

53 ion is mediated, at least in part, through a ubiquitin-proteasome pathway.

54 protein levels of Runx2 are regulated by the ubiquitin-proteasome pathway.

55 eptors are ubiquitinated and degraded by the ubiquitin-proteasome pathway.

56 ucleus to the cytoplasm and degraded via the ubiquitin-proteasome pathway.

57 eavage of cellular and viral proteins by the ubiquitin-proteasome pathway.

58 or retrotranslocation and degradation by the ubiquitin-proteasome pathway.

59 the KLF5 protein is tightly regulated by the ubiquitin-proteasome pathway.

60 ssociation with Hsp90 and degradation by the ubiquitin-proteasome pathway.

61 of inhibitor of nuclear factor kappaB by the ubiquitin-proteasome pathway.

62 adation of selected proteins in vivo via the ubiquitin-proteasome pathway.

63 le protein that is actively degraded via the ubiquitin-proteasome pathway.

64 isms by which apoptosis are regulated by the ubiquitin-proteasome pathway.

65 lls are targeted for degradation through the ubiquitin-proteasome pathway.

66 the transcription factor MyoD occurs via the ubiquitin-proteasome pathway.

67 of a bile acid transporter expression by the ubiquitin-proteasome pathway.

68 tely 6 h) whose degradation depends upon the ubiquitin-proteasome pathway.

69 t p73 stability is directly regulated by the ubiquitin-proteasome pathway.

70 cted miR-30 targets, as well as genes in the ubiquitin-proteasome pathway.

71 a, HIF-1alpha is constantly degraded via the ubiquitin-proteasome pathway.

72 central problem concerning the design of the ubiquitin-proteasome pathway.

73 s of several regulatory proteins through the ubiquitin-proteasome pathway.

74 eurofibromin is dynamically regulated by the ubiquitin-proteasome pathway.

75 BEC3G by targeting it for destruction by the ubiquitin-proteasome pathway.

76 R-induced degradation of Hdm2 occurs via the ubiquitin-proteasome pathway.

77 of a short-lived GFP that is degraded by the ubiquitin-proteasome pathway.

78 MEPA1 with the NEDD4 protein involved in the ubiquitin-proteasome pathway.

79 ds and induces proteolysis of Rb through the ubiquitin-proteasome pathway.

80 ded proteins destined for degradation by the ubiquitin-proteasome pathway.

81 KRT10, targeting it for degradation via the ubiquitin-proteasome pathway.

82 ein is known to destabilize myogenin via the ubiquitin-proteasome pathway.

83 (s), at least one of which is related to the ubiquitin-proteasome pathway.

84 tein level, degradation was mediated via the ubiquitin-proteasome pathway.

85 diating HIF-1alpha protein stability via the ubiquitin-proteasome pathway.

86 l that stimulates RASSF1A degradation by the ubiquitin-proteasome pathway.

87 ant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway.

88 drugs bortezomib and carfilzomib target the ubiquitin-proteasome pathway.

89 hat the HMGS-1 level is also governed by the ubiquitin-proteasome pathway.

90 ch targeted ER-alpha degradation through the ubiquitin-proteasome pathway.

91 li, IkappaBalpha is rapidly degraded via the ubiquitin-proteasome pathway.

92 APOBEC3F (A3F) for degradation via the host ubiquitin-proteasome pathway.

93 xecutes the degradation of substrates of the ubiquitin-proteasome pathway.

94 in promotes the degradation of STAT3 via the ubiquitin-proteasome pathway.

95 graded in response to DNA damage through the ubiquitin-proteasome pathway.

96 m being subjected to degradation through the ubiquitin-proteasome pathway.

97 s an essential intracellular protease of the ubiquitin-proteasome pathway.

98 I1), which results in JAZ degradation by the ubiquitin-proteasome pathway.

99 teasome operates at the executive end of the ubiquitin-proteasome pathway.

100 by targeting it for degradation through the ubiquitin-proteasome pathway.

101 response system and are degraded through the ubiquitin-proteasome pathway.

102 to Hsp90, which directed the protein to the ubiquitin-proteasome pathway.

103 inute 2, protected synapses, implicating the ubiquitin-proteasome pathway.

104 ype ubiquitin ligase for degradation via the ubiquitin-proteasome pathway.

105 vidence that Ikaros degradation involves the ubiquitin/proteasome pathway.

106 monly initiates their downregulation via the ubiquitin/proteasome pathway.

107 we show that KRP1 is a likely target of the ubiquitin/proteasome pathway.

108 d GATA-1 is targeted for degradation via the ubiquitin/proteasome pathway.

109 se protein substrates for degradation by the ubiquitin/proteasome pathway.

110 efficacy of anticancer drugs that target the ubiquitin/proteasome pathway.

111 ween RNA polymerase II transcription and the ubiquitin/proteasome pathway.

112 duce the protein level of c-IAPs through the ubiquitin/proteasome pathway.

113 adation of nascent class I molecules via the ubiquitin/proteasome pathway.

114 broadly affects protein degradation via the ubiquitin/proteasome pathway.

115 ute to the demise of protein turnover by the ubiquitin/proteasome pathway.

116 Pak1 phosphorylation and beta-TrCP-dependent ubiquitin-proteasome pathways.

117 n activation to deplete p38gamma proteins by ubiquitin-proteasome pathways.

118 member p38gamma protein via c-Jun-dependent ubiquitin-proteasome pathways.

119 growth factor-beta signaling and activity of ubiquitin-proteasome pathways.

120 increase the expression and activity of the ubiquitin-proteasome pathway, a major proteolytic mechan

121 mediated by protein degradation through the ubiquitin-proteasome pathway, a mechanism related to tha

122 Interference of the ubiquitin-proteasome pathway affected RTA-mediated trans

123 hown to function both as an E3 ligase in the ubiquitin proteasome pathway and as a transcriptional co

124 Together, our results identify the ubiquitin proteasome pathway and CUL2 as important regul

125 rgets for new agents in lymphoma include the ubiquitin proteasome pathway and the biochemical reactio

126 Here we investigate direct links between the ubiquitin-proteasome pathway and ataxin-3.

127 wn-regulation of MARK4 protein level through ubiquitin-proteasome pathway and inhibition of MARK4 kin

128 and EVI1 moieties and degrades EVI1 via the ubiquitin-proteasome pathway and MDS1 in a proteasome-in

129 lti-protein complex that interfaces with the ubiquitin-proteasome pathway and plays critical developm

130 on of P-glycoprotein can be regulated by the ubiquitin-proteasome pathway and suggest that modulating

131 6AP is a component of ER degradation via the ubiquitin-proteasome pathway and that Ca(2+)/calmodulin

132 on of cis-acting degradation signals and the ubiquitin-proteasome pathway and that modulation of Fad3

133 RTA can induce K-RBP degradation through the ubiquitin-proteasome pathway and that two regions in RTA

134 ed virus budding has been linked to both the ubiquitin-proteasome pathway and the vacuolar protein-so

135 turnover of eEF-2 kinase is regulated by the ubiquitin-proteasome pathway and, therefore, modulating

136 y to melanosomes and its degradation via the ubiquitin-proteasome pathway and/or the endosomal/lysoso

137 e examined the functional involvement of the ubiquitin/proteasome pathway and rate-limiting aspects o

138 CYP2E1 is degraded by the ubiquitin-proteasome pathway, and because the hsp90/hsp7

139 he level of MSH2 protein is modulated by the ubiquitin-proteasome pathway, and histone deacetylase 6

140 m (ER)-associated degradation (ERAD) via the ubiquitin-proteasome pathway, and inhibition of proteaso

141 Proteolysis by the ubiquitin-proteasome pathway appears to have a complex r

142 Various components of the ubiquitin-proteasome pathway are differentially regulate

143 Thus, when nuclear substrates of the ubiquitin-proteasome pathway are not efficiently degrade

144 isfolding of proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogene

145 Together, our results identify the ubiquitin-proteasome pathway as a biomarker of poor prog

146 roliferation and encystation, suggesting the ubiquitin-proteasome pathway as a viable therapeutic tar

147 d Cx43 degradation is likely mediated by the ubiquitin-proteasome pathway, as (i) treatment with prot

148 FL SIRT3 degradation is mediated by the ubiquitin-proteasome pathway, at least partially through

149 n is at least partially mediated through the ubiquitin-proteasome pathway because proteasome inhibito

150 any human cancers and may be degraded by the ubiquitin-proteasome pathway, but components of the path

151 nduces degradation of DELLA proteins via the ubiquitin/proteasome pathway, but light promotes accumul

152 of LSD1 occurs posttranscriptionally via the ubiquitin-proteasome pathway by an E3 ubiquitin ligase,

153 ibitor of mTORC1 and mTORC2, is degraded via ubiquitin-proteasome pathway by an unknown E3 ubiquitin

154 The regulated degradation of AT1R via a ubiquitin/proteasome pathway by activation of D5R provid

155 ring tumorigenesis, negatively regulates the ubiquitin/proteasome pathway by interfering with protein

156 results show that homeostatic control of the ubiquitin-proteasome pathway can be achieved through sig

157 We conclude that the competition of ubiquitin-proteasome pathway components for surfaces on

158 suggesting that decreased expression of the ubiquitin-proteasome pathway components may contribute t

159 Thus, ubiquitin-proteasome pathway control of G1-to-S-phase pr

160 Thus, these results show that the ubiquitin-proteasome pathway controls the critical devel

161 sm and accelerated the degradation of Id2 by ubiquitin-proteasome pathway during osteogenesis.

162 ion licensing factor Cdt1 is degraded by the ubiquitin-proteasome pathway during S phase of the cell

163 n transcription and proteins involved in the ubiquitin-proteasome pathway encompasses both proteolyti

164 Regulated protein degradation by the ubiquitin-proteasome pathway ensures the unidirectionali

165 ch target-directed proteolysis of AGO by the ubiquitin-proteasome pathway exposes the miRNA for degra

166 FOXO1, FOXO3, NFKB1A), key components of the ubiquitin proteasome pathway (FBXO32, TRIM63, CBLB), and

167 de BOK via the ER-associated degradation and ubiquitin-proteasome pathways; following proteasome inhi

168 domain, which targets the protein toward the ubiquitin proteasome pathway for degradation.

169 nt approaches that exploit components of the ubiquitin-proteasome pathway for amelioration of these d

170 6S proteasome is at the executive end of the ubiquitin-proteasome pathway for the controlled degradat

171 nificance of the endogenous Siah-1-dependent ubiquitin/proteasome pathway for beta-catenin degradatio

172 The ubiquitin/proteasome pathway for degradation of complete

173 te synaptic strength and growth and that the ubiquitin proteasome pathway functions in mature neurons

174 eased the expression of proteasome and other ubiquitin-proteasome pathway genes.

175 uggest that the nuclear N terminus-dependent ubiquitin proteasome pathway governs PGC-1alpha cellular

176 ur recent studies have demonstrated that the ubiquitin proteasome pathway has an important role in th

177 In recent years, proteolysis by the ubiquitin-proteasome pathway has attained prominence as

178 Although the ubiquitin-proteasome pathway has been established as one

179 The ubiquitin-proteasome pathway has been identified as a po

180 The ubiquitin-proteasome pathway has been implicated in syna

181 Selective protein degradation by the ubiquitin-proteasome pathway has emerged as a key regula

182 The ubiquitin-proteasome pathway has emerged as an important

183 The proteasome, a key component of the ubiquitin-proteasome pathway, has emerged as an importan

184 ein levels of some signaling proteins by the ubiquitin proteasome pathway; however, the cellular mech

185 easome inhibitors, suggesting a role for the ubiquitin proteasome pathway in apoptosis.

186 s for Claspin, Rad17 phosphorylation and the ubiquitin proteasome pathway in Chk1 signaling.

187 The durability of the ubiquitin proteasome pathway in the mammalian lens makes

188 n of replication-dependent DSBs requires the ubiquitin-proteasome pathway in CPT-treated cells.

189 use models, as well as investigations of the ubiquitin-proteasome pathway in disease pathogenesis.

190 of this work was to explore the role of the ubiquitin-proteasome pathway in eliminating S-glutathiol

191 irpin RNA screen targeting components of the ubiquitin-proteasome pathway in human cells, we identifi

192 rovide very appealing tools for studying the ubiquitin-proteasome pathway in intact mammalian cells b

193 ere we show that GSK3beta is degraded by the ubiquitin-proteasome pathway in murine lung epithelial c

194 ulating evidence points to a key role of the ubiquitin-proteasome pathway in oncogenesis.

195 ted and that PML protein is degraded via the ubiquitin-proteasome pathway in productively infected ce

196 een shown to be rapidly degraded through the ubiquitin-proteasome pathway in response to cholesterol

197 In this study we examined the role of the ubiquitin-proteasome pathway in the degradation of the L

198 ut mouse model, we evaluated the role of the ubiquitin-proteasome pathway in the development of contr

199 has led to investigations of the role of the ubiquitin-proteasome pathway in the pathogenesis of myel

200 f studies now indicate multiple roles of the ubiquitin-proteasome pathway in the regulation and maint

201 To investigate the involvement of the ubiquitin-proteasome pathway in the regulation of the st

202 celerated muscle proteolysis mediated by the ubiquitin-proteasome pathway in various catabolic condit

203 An important role for the ubiquitin-proteasome pathways in beta-cells is suggested

204 cell signaling causes Bok degradation by the ubiquitin-proteasome pathway, in a manner that parallels

205 corroborated using several inhibitors of the ubiquitin proteasome pathway, including PS-341, an antic

206 hese damaged cytosolic proteins requires the ubiquitin-proteasome pathway, including the E2s UBC4/UBC

207 ion of caspase-8 and -9 and caspase-mediated ubiquitin-proteasome pathway-independent loss of cyclin

208 therapy suggest that drugs that disrupt the ubiquitin/proteasome pathway induce apoptosis and sensit

209 s aspects of nucleic acid metabolism and the ubiquitin-proteasome pathway intersect in several direct

210 kp1-cullin-F-box complex associated with the ubiquitin-proteasome pathway involved in auxin signaling

211 regulation of histone protein levels by the ubiquitin-proteasome pathway involving the E2 ubiquitin

212 NPMc degradation was mediated by the ubiquitin-proteasome pathway involving the IBR-type RING

213 The ubiquitin proteasome pathway is critical in restraining

214 The ubiquitin proteasome pathway is involved in the regulati

215 indicate that the regulation of Atoh1 by the ubiquitin proteasome pathway is necessary for hair cell

216 The ubiquitin proteasome pathway is responsible for most of

217 The ubiquitin-proteasome pathway is a major protein degradat

218 The ubiquitin-proteasome pathway is a vital component of cel

219 rophy and contractile weakness, and that the ubiquitin-proteasome pathway is activated in the diaphra

220 the diaphragm of critically ill patients the ubiquitin-proteasome pathway is activated.

221 The ubiquitin-proteasome pathway is critical to this quality

222 The ubiquitin-proteasome pathway is crucial for protein turn

223 The ubiquitin-proteasome pathway is essential throughout the

224 The ubiquitin-proteasome pathway is involved in regulation o

225 of the regulation of TRAIL signaling in the ubiquitin-proteasome pathway is mediated by the inhibito

226 Their rapid turnover by the ubiquitin-proteasome pathway is regulated through phosph

227 The data show that proteolysis through the ubiquitin-proteasome pathway is required for bFGF-induce

228 The ubiquitin-proteasome pathway is the major nonlysosomal p

229 Accelerated protein degradation via the ubiquitin-proteasome pathway is the principal cause of s

230 The ubiquitin/proteasome pathway is a well characterized sys

231 tion as regulated protein degradation by the ubiquitin/proteasome pathway is essential for neuronal s

232 the Varshavsky laboratory revealed that the ubiquitin/proteasome pathway is the principal system for

233 During protein degradation by the ubiquitin-proteasome pathway, latent 26S proteasomes in

234 omplexes arrest transcription and activate a ubiquitin-proteasome pathway leading to the degradation

235 y proteins that are normally degraded by the ubiquitin-proteasome pathway like cyclins, p53, and Ikap

236 tion of cell death-promoting proteins by the ubiquitin-proteasome pathway may represent a novel thera

237 ethylene, EIN3 is quickly degraded through a ubiquitin/proteasome pathway mediated by two F-box prote

238 plexes by molecular chaperones, or a slower, ubiquitin-proteasome-pathway-mediated turnover of DNA-bo

239 In broader terms, the function of the ubiquitin-proteasome pathway might be regulated physiolo

240 Consistently, a chemical inhibitor of the ubiquitin proteasome pathway mitigated the disrupting ef

241 ved and linked to an early activation of the ubiquitin proteasome pathway, myosin:actin ratios were n

242 These results reveal that a ubiquitin/proteasome pathway negatively regulates ethyle

243 urther shown that HDACs are degraded via the ubiquitin/proteasome pathway, opening up a search for th

244 fted either through DELLA proteolysis by the ubiquitin-proteasome pathway or through proteolysis-inde

245 Levels of typical substrates for the ubiquitin-proteasome pathway, p21(WAF) and p27(Kip), wer

246 These studies reveal that the ubiquitin-proteasome pathway participates in regulating

247 Strikingly, the ubiquitin-proteasome pathway plays a central part in mos

248 The ubiquitin-proteasome pathway plays a central role in reg

249 The ubiquitin-proteasome pathway plays an important role in

250 The ubiquitin/proteasome pathway plays critical roles in vir

251 MG132 and lactacystin, inhibitors of the ubiquitin-proteasome pathway, prevented the calmodulin a

252 pmental proteins (OFD1), and proteins of the ubiquitin-proteasome pathway (PSMC1).

253 The ubiquitin-proteasome pathway regulates the degradation o

254 Therefore, we determined whether the ubiquitin-proteasome pathway regulates the turnover of e

255 epidopteran RNAi, Nuclear Factor-kappaB, and ubiquitin-proteasome pathways restrict RNA virus infecti

256 ions, these repressors are destroyed via the ubiquitin-proteasome pathway, resulting in derepression/

257 lts, these data support the concept that the ubiquitin-proteasome pathway serves as a general protein

258 Expression of other members of the ubiquitin-proteasome pathway studied after culturing isl

259 plexities of ubiquitination of an endogenous ubiquitin-proteasome pathway substrate in unperturbed ma

260 Better mechanisms to inhibit the ubiquitin-proteasome pathway targeted at the ubiquitin-p

261 erg1a in mouse skeletal muscle activates the ubiquitin proteasome pathway that is responsible for the

262 ced down-regulation of FLIP is mediated by a ubiquitin-proteasome pathway that is negatively regulate

263 UbcH6-RING105 may define a novel ubiquitin-proteasome pathway that targets TSSC5 in mamma

264 that Sts1 is a new regulatory factor in the ubiquitin/proteasome pathway that controls the turnover

265 suggested many novel roles, including in the ubiquitin proteasome pathway, that warrant further explo

266 the level of MutSalpha can be reduced by the ubiquitin-proteasome pathway, the detailed mechanisms of

267 REBP and cleavage requires components of the ubiquitin-proteasome pathway: the E2-conjugating enzyme

268 n, inhibiting the degradation induced by the ubiquitin-proteasome pathway, thereby increasing Drosha

269 ized beta-catenin expression by blocking the ubiquitin-proteasome pathway, thereby promoting CRC deve

270 an be controlled post-translationally by the ubiquitin-proteasome pathway through a mechanism that de

271 xported to the cytoplasm and degraded by the ubiquitin-proteasome pathway through a process called ER

272 elated Modifier) pathway crosstalks with the ubiquitin-proteasome pathway to affect TOC159 stability

273 viral APOBEC3 (A3) proteins through the host ubiquitin-proteasome pathway to enable viral immune evas

274 Among the roles of the ubiquitin proteasome pathway (UPP) is protein surveillan

275 We targeted p97/VCP, the ubiquitin proteasome pathway (UPP), and autophagy with c

276 the GeneChip included genes involved in the ubiquitin proteasome pathway (UPP), metallothionein func

277 We investigated herein the involvement of ubiquitin-proteasome pathway (UPP) and autophagy, two ma

278 present study was to explore the role of the ubiquitin-proteasome pathway (UPP) in degrading C-termin

279 To inhibit the ubiquitin-proteasome pathway (UPP) in vivo, lactacystin

280 We previously demonstrated that the ubiquitin-proteasome pathway (UPP) is a general protein

281 Dysfunction of the ubiquitin-proteasome pathway (UPP) is associated with se

282 The ubiquitin-proteasome pathway (UPP) is involved in regula

283 The ubiquitin-proteasome pathway (UPP) is responsible for mo

284 The ubiquitin-proteasome pathway (UPP) is the main route of

285 The ubiquitin-proteasome pathway (UPP) plays a role in selec

286 Furthermore, we show that the ubiquitin-proteasome pathway (UPP) regulates NER via two

287 The ubiquitin-proteasome pathway (UPP) regulates synaptic fu

288 Although rates of protein degradation by the ubiquitin-proteasome pathway (UPS) are determined by the

289 is rapidly induced and then targeted to the ubiquitin-proteasome pathway via a mechanism that requir

290 The ubiquitin proteasome pathway was the common pathway in r

291 Further, we found that the ubiquitin/proteasome pathway was responsible for MeCP2 T

292 rminal hydrolase L1 (UCHL1), a member of the ubiquitin proteasome pathway, was consistently up-regula

293 Proteins of the ubiquitin-proteasome pathway were rapidly upregulated af

294 In old mice, genes that are involved in the ubiquitin-proteasome pathway were significantly down-reg

295 Markers of the ubiquitin-proteasome pathway were significantly up-regul

296 system for protein stability is given by the ubiquitin proteasome pathway, which uses E3 ligases to m

297 E1 (COI1) causes degradation of JAZs via the ubiquitin-proteasome pathway, which in turn activates th

298 expressed functional gene categories was the ubiquitin-proteasome pathway, which was upregulated in b

299 nases, and/or ubiquitin receptors within the ubiquitin proteasome pathway, with an aim to achieve mor

300 ation is a key step in the regulation of the ubiquitin-proteasome pathway, yet the mechanisms underly